US 12,246,014 B2
Azetidine derivatives
Stephen Roughley, Great Abington (GB); Steven Walls, Great Abington (GB); Terance Hart, Great Abington (GB); Rachel Parsons, Great Abington (GB); Paul Brough, Great Abington (GB); Christopher Graham, Great Abington (GB); and Alba Macias, Great Abington (GB)
Assigned to Ligand UK Development Limited, Great Abington (GB)
Filed by Ligand UK Development Limited, Great Abington (GB)
Filed on Jan. 14, 2021, as Appl. No. 17/148,785.
Application 13/866,059 is a division of application No. 12/920,181, granted, now 8,450,346, issued on May 28, 2013, previously published as PCT/GB2009/000568, filed on Feb. 27, 2009.
Application 17/148,785 is a continuation of application No. 16/506,225, filed on Jul. 9, 2019, granted, now 10,918,640.
Application 16/506,225 is a continuation of application No. 15/278,386, filed on Sep. 28, 2016, granted, now 10,383,871, issued on Aug. 20, 2019.
Application 15/278,386 is a continuation of application No. 14/641,783, filed on Mar. 9, 2015, granted, now 9,475,800, issued on Oct. 25, 2016.
Application 14/641,783 is a continuation of application No. 13/866,059, filed on Apr. 19, 2013, granted, now 9,006,269, issued on Apr. 14, 2015.
Claims priority of application No. 0804006 (GB), filed on Mar. 4, 2008; and application No. 0821694 (GB), filed on Nov. 27, 2008.
Prior Publication US 2021/0267974 A1, Sep. 2, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/396 (2006.01); A61K 31/397 (2006.01); A61K 31/4427 (2006.01); A61K 31/4439 (2006.01); A61K 31/495 (2006.01); A61K 31/497 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); C07D 205/04 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 413/14 (2006.01)
CPC A61K 31/506 (2013.01) [A61K 31/397 (2013.01); A61K 31/4427 (2013.01); A61K 31/4439 (2013.01); A61K 31/495 (2013.01); A61K 31/497 (2013.01); A61K 31/501 (2013.01); C07D 205/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 413/14 (2013.01)] 10 Claims
 
1. A method of treatment of a disease or medical condition which benefits from inhibition of FAAH activity, wherein the disease or condition is renal ischemia, comprising administering to a subject suffering renal ischemia an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein
Ar1 is optionally substituted phenyl;
Ar2 is optionally substituted phenyl, optionally substituted pyridyl, optionally substituted pyrimidinyl, optionally substituted pyrazinyl, optionally substituted pyridazinyl or optionally substituted oxadiazolyl; and
Ar3 is a divalent radical selected from the group consisting of optionally substituted phenylene and optionally substituted pyridinylene.